PTSD and Alcohol Use Disorder: Co-Occurrence, Mechanisms, and Integrated Treatment

Overview

Post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) are two of the most common and disabling mental health conditions in the world. When they occur together — which happens far more often than chance would predict — the result is not simply "two problems at once." The combination is synergistic: each condition makes the other harder to treat, and together they carry risks that dwarf either disorder alone.

For decades, the standard clinical approach was sequential: get sober first, then address the trauma. That model is now outdated. A growing body of evidence shows that integrated treatment — addressing PTSD and AUD simultaneously — produces better outcomes than treating one condition while waiting on the other. This article synthesizes the best available evidence on why PTSD and AUD co-occur so reliably, what drives the relationship, and what treatments actually work.

The stakes are high. A Swedish birth cohort study of nearly 860,000 individuals found that comorbid PTSD and AUD accounted for 71 to 179 additional suicide attempt cases per 10,000 person-years beyond what either disorder contributed independently ^[1] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). That is not an additive risk — it is a synergistic one, and it makes the urgency of integrated care a matter of life and death.

Epidemiology: How Common Is This Comorbidity?

PTSD affects approximately 3.9% of people worldwide over their lifetime, rising to 5.6% among those who have experienced trauma ^[2]. These figures establish the baseline, but the comorbidity picture is considerably more striking.

Among people in substance use disorder (SUD) treatment, roughly 25% meet criteria for probable PTSD, with an additional 15% showing subclinical PTSD symptoms ^[3]. Veterans are disproportionately affected: nationally representative data from the 2019–2020 National Health and Resilience in Veterans Study (N = 4,069) confirm elevated rates of comorbid PTSD and AUD in post-9/11 veterans relative to civilians ^[4]. Among first responders, a nationwide South Korean survey of 54,054 firefighters found that 2.3% fell into a "high symptoms and comorbidity" class encompassing PTSD, depression, AUD, and insomnia simultaneously ^[5].

Comorbidity is consistently associated with more severe symptoms, greater functional impairment, increased suicide risk, and poorer treatment outcomes compared to either disorder alone ^[6].

Gender Differences

Sex and gender shape both the prevalence and the pathway into comorbidity. A narrative review of sex and gender differences concludes that intertwining biological systems increase females' risk of developing PTSD and experiencing more adverse effects from AUD compared to males, while also identifying distinct sociocultural pathways ^[7]. The Swedish birth cohort data found that females whose PTSD precedes AUD carry a particularly elevated burden of comorbidity in terms of suicide attempt risk ^[1] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication).

In a Japanese population study (N = 6,180), the AUD group comprised more men (59.1%) than the non-AUD group (44.1%), and trauma type interacted with gender: physical violence by a partner was associated with higher AUD risk in men, while women showed elevated AUD risk from several non-natural-disaster trauma types ^[8].

Importantly, the corpus has a significant gap here: there are no nationally representative civilian prevalence estimates with sex-stratified, race-stratified, and age-stratified comorbidity rates. Population-level data on non-binary and transgender individuals are also absent — a gap explicitly noted in the literature ^[7].

The Bidirectional Relationship

PTSD and AUD do not simply co-occur — they actively reinforce each other through multiple pathways. Understanding this bidirectionality is essential to understanding why neither condition gets better when only one is treated.

PTSD → AUD

The most well-documented pathway runs from trauma and PTSD toward alcohol use. PTSD symptoms — hyperarousal, intrusive memories, nightmares, emotional numbing — are profoundly uncomfortable, and alcohol provides rapid, reliable, if temporary relief. Ecological momentary assessment (EMA) data collected across 3,024 real-world observations found that coping drinking motives significantly moderated the relationship between PTSD symptoms and alcohol craving in real time: when PTSD symptoms were elevated and a person was already oriented toward drinking to cope, craving intensified dramatically ^[9]. This is not a trait-level pattern — it is a moment-to-moment functional process.

Among Black and African American adults with heavy alcohol use, PTSD symptoms mediated the relationship between trauma exposure and drinks per typical drinking day ^[10], further supporting the self-medication pathway across diverse populations.

AUD → PTSD

The relationship also runs in the other direction. Alcohol use increases exposure to traumatic events — through accidents, violence, and risky situations that occur during intoxication. Beyond exposure, alcohol impairs the brain's ability to process and extinguish traumatic memories. As one analysis puts it, alcohol use "dulls the emotional response and promotes disengagement from the traumatic memory," and over time this "strengthens posttraumatic distress by reinforcing the belief that traumatic memories and their emotional responses are themselves dangerous and intolerable" ^[11]. Every drink that works in the short term teaches the nervous system that it cannot survive the memory without chemical help.

The temporal ordering of onset matters. The Swedish birth cohort data found that AUD preceding PTSD was associated with more pronounced interaction effects on suicide attempt risk than the reverse ordering ^[1] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication) — a population-level signal that the direction of onset has real clinical relevance.

The Self-Medication Hypothesis

The self-medication hypothesis — originally articulated by Khantzian — holds that substance use is not random or purely compulsive but functionally targeted: people use specific substances because those substances address specific symptoms. In PTSD-AUD, the fit is almost pharmacologically precise.

Alcohol's GABA-mediated anxiolytic effects quiet the hyperarousal that makes PTSD so exhausting. It blunts intrusive memories, suppresses nightmares, and makes sleep possible — at least initially. The EMA data from ^[9] document this as a real-time process: PTSD symptoms drive craving most powerfully when coping motives are already elevated, suggesting that the drinking is purposeful, not incidental.

The limitation of this functional system is built into its mechanism. Tolerance develops, requiring more alcohol to achieve the same relief. Withdrawal — particularly alcohol withdrawal — produces a rebound hyperarousal that is often worse than the original PTSD symptoms. The neurobiological evidence from animal models suggests that chronic alcohol exposure damages the same hippocampal circuits that trauma-focused therapies are trying to restore ^[12]. The short-term solution becomes the long-term obstacle.

Self-medication is real. It is not a character flaw or a failure of willpower. It is a functional pain management system operating under conditions of inadequate treatment — and understanding it as such is the foundation of effective care.

Neurobiology: Why These Conditions Share a Brain

The co-occurrence of PTSD and AUD is not merely phenomenological — it reflects shared and interacting neurobiological pathways.

The cAMP-PKA Pathway and Hippocampal Damage

The most mechanistically detailed evidence in the current literature comes from animal model work demonstrating that both chronic alcohol exposure and traumatic stress produce synaptic damage in the hippocampus through convergent pathways ^[12]. Alcohol-exposed mice showed more pronounced deficits in fear extinction and higher anxiety-like behavior following stress exposure. Activation of the cAMP-PKA signaling pathway reversed these effects by modulating BDNF/TrkB downregulation and restoring AMPA and NMDA receptor expression in the CA1 region of the hippocampus ^[12].

This is a compelling mechanistic story: alcohol and trauma both damage the hippocampal circuits that support fear extinction — the very process that trauma-focused therapies like Prolonged Exposure (PE) and Cognitive Processing Therapy (CPT) are designed to engage. It is important to note, however, that this evidence comes from animal models, and the corpus does not contain human neuroimaging or HPA-axis studies that would confirm this pathway clinically.

Human Neuroimaging Evidence

A human fMRI study adds a complementary layer: compared to people with PTSD alone, those with comorbid PTSD and alcohol dependence showed significant deactivations in visual processing and memory regions (left middle occipital gyrus, right lingual gyrus), with alcohol dependence severity correlating with right lingual gyrus deactivation ^[13]. The authors frame these as evidence of implicit emotion regulation deficits — and as potential neural diagnostic markers of the comorbid state. This is consistent with the self-medication framework: alcohol temporarily dampens hyperactivated threat-detection circuitry, but at the cost of impairing the neural substrate for emotional processing and extinction learning.

Genetic Architecture

The genetic epidemiology adds an important nuance. Using genomic structural equation modeling on large-scale GWAS data, researchers found that alcohol use and AUD have different genetic relationships with PTSD: AUD shows a positive genetic correlation with PTSD (rG = 0.36–0.40), while alcohol use quantity shows a negative genetic correlation (rG = -0.17 to -0.57) ^[14]. This striking divergence suggests that "drinking in PTSD" is not a unitary phenomenon — the pathway from PTSD to AUD (a disorder) may be genetically distinct from the pathway to heavy drinking per se. This has potential implications for treatment targeting, though the clinical translation of genomic findings remains an active area of research.

Integrated Treatment Models

The central clinical message from the available evidence is clear: integrated treatment — addressing PTSD and AUD simultaneously — is the modern standard of care. The older "stabilize first" model, which required patients to achieve sobriety before trauma-focused therapy could begin, is not supported by current evidence and imposes real harm through delay.

Cognitive Processing Therapy + Relapse Prevention (CPT+RP)

The CPT+RP integration combines trauma-focused cognitive restructuring with evidence-based relapse prevention skills. A case series demonstrated pre-to-post reductions in PTSD symptoms (ΔCAPS-5 = 14.00; ΔPCL-5 = 20.50), alongside meaningful reductions in drinking frequency (ΔPDD = 38.65%) and drinks per drinking day (ΔDDD = 6.24), with high acceptability ratings among participants with active AUD ^[15]. A full Stage II RCT comparing CPT+RP to relapse prevention alone (target N = 200) is now underway ^[6]. These are preliminary findings from a small case series, but the signal is consistent with the broader integrated treatment literature.

PC-TIME: Brief Primary Care Integration

PC-TIME (Primary Care Trauma-Integrated Motivational Enhancement) combines motivational interviewing with brief prolonged exposure in a primary care setting. A randomized controlled pilot trial (N = 63) found that PC-TIME produced significantly steeper decreases in both PTSD severity and heavy drinking days compared to treatment as usual ^[16]. This is particularly important because it demonstrates feasibility outside specialty mental health settings — where most people with PTSD-AUD actually present.

BRITE: Brief CPT-Adapted Intervention

Among recent sexual assault survivors with PTSD symptoms and alcohol misuse, a brief CPT-adapted intervention (BRITE) demonstrated significantly greater PTSD symptom reduction in the intervention arm (d = 2.69) compared to symptom monitoring (d = 1.19) ^[17]. Mediation analyses found that trauma cognitions improved with the intervention, though mediation effects for alcohol outcomes were small and non-significant ^[18] — suggesting that cognitive change alone may not fully explain alcohol outcomes, and that additional mechanisms are operating.

Prolonged Exposure in Active Drinkers

A long-held clinical fear was that delivering trauma-focused therapy to people who are actively drinking would destabilize their recovery — that confronting traumatic memories without sobriety as a foundation would trigger relapse or worsen drinking. The available evidence does not support this fear.

The Norman et al. RCT ^[19] enrolled 100 U.S. veterans with both PTSD and AUD — 84% men, mean age 45 — and delivered Prolonged Exposure to all participants regardless of drinking status. Both treatment conditions showed significant reductions in heavy drinking days. PE did not worsen drinking. Trauma processing did not destabilize recovery. This directly refutes the stabilize-first model.

The CPT+RP case series ^[15] and the PC-TIME pilot ^[16] tell the same story: integrated trauma-focused treatment reduces both PTSD symptoms and alcohol use simultaneously, in active drinkers, without requiring prior abstinence.

It is worth noting that the corpus does not answer the dose-response question: whether patients drinking at very high quantities daily respond differently to PE than those with moderate use. That question remains open. But the available evidence does not support withholding trauma-focused therapy from people with active AUD as a general policy.

Topiramate for PTSD-AUD: The Norman 2025 Trial

The most rigorous pharmacological trial in the current evidence base is Norman et al.'s double-blind, placebo-controlled RCT of Prolonged Exposure plus topiramate (up to 250 mg/day) versus PE plus placebo in 100 U.S. veterans with PTSD and AUD ^[19].

The key findings ^[19]:

• PE + topiramate produced greater PTSD symptom reduction at post-treatment, with higher rates of PTSD diagnosis loss and meaningful symptom change compared to PE + placebo
• This PTSD advantage was not maintained at 3- or 6-month follow-up
• Topiramate conferred no added benefit over PE alone for percent heavy drinking days — both conditions reduced heavy drinking significantly

This is a nuanced result that deserves careful interpretation. Topiramate appears to accelerate PTSD symptom reduction during active treatment — a clinically meaningful finding for patients in acute distress — but does not sustain that advantage after treatment ends, and does not address the AUD component beyond what PE alone achieves. The dissociation between topiramate's effect on negative affect (PTSD symptoms) and its lack of effect on reward-driven heavy drinking suggests these may be partially separable targets requiring different interventions.

The implication is not that topiramate is ineffective, but that pharmacological augmentation of trauma-focused therapy may need to be extended beyond the acute treatment phase, and that targeted AUD pharmacotherapy may need to be added alongside.

Other Pharmacotherapy Options

The pharmacotherapy evidence base for PTSD-AUD is genuinely thin, and clinicians should approach it with appropriate humility. Several agents have evidence worth knowing:

Sertraline and Paroxetine

Both sertraline and paroxetine are FDA-approved for PTSD and have modest evidence for AUD effects. A secondary analysis of an RCT (N = 128) found that desipramine showed better drinking outcomes in patients with PTSD (with or without comorbid depression), while paroxetine was superior for depressive symptoms overall ^[20]. This suggests that noradrenergic versus serotonergic mechanisms may matter differentially depending on the comorbidity profile — a clinically important distinction that is often overlooked.

Naltrexone

The older pharmacological literature identifies the sertraline plus naltrexone combination as having the largest effect size in the available evidence, though both systematic reviews characterize this evidence as "limited and partly contradictory" ^[21]. Naltrexone is FDA-approved for AUD and has some evidence in PTSD contexts, but the corpus does not contain adequately powered veteran-specific trials of naltrexone monotherapy for PTSD-AUD.

Prazosin

Prazosin — an alpha-1 adrenergic antagonist — has historically been used for PTSD-related nightmares and hyperarousal, with a plausible mechanism and earlier supportive evidence. However, a large VA-based RCT (Raskind et al., 2018) produced a negative result, failing to show benefit over placebo for nightmares in veterans. This trial is not directly represented in the current corpus, but its findings are part of the clinical landscape and represent an important nuance: the earlier enthusiasm for prazosin has been tempered by more rigorous testing. Clinical use continues in some settings, particularly for patients with prominent nightmare symptoms, but the evidence base is now contested.

N-Acetylcysteine (NAC)

NAC has generated interest as a potential dual-target agent given its glutamatergic and antioxidant mechanisms. A 2026 meta-analysis of 7 RCTs (N = 566) found no significant differences from placebo on craving (SMD = -0.40, 95% CI [-1.05, 0.25], p = 0.22) or PTSD severity by either PCL or CAPS scales ^[22]. A sensitivity analysis excluding one outlier study did yield a significant signal favoring NAC for PTSD (SMD = -0.35, p = 0.04), but with substantial heterogeneity throughout. This cannot be considered definitive evidence of efficacy. The null result across pooled analyses is consistent with the genomic evidence suggesting that PTSD-AUD is a genetically heterogeneous comorbidity unlikely to respond uniformly to a single-pathway intervention ^[14].

Veterans

Veterans — particularly those who served in Iraq and Afghanistan — carry an elevated burden of comorbid PTSD and AUD relative to civilians ^[4]. Among post-9/11 veterans, PTSD confers a hazard ratio of 2.42 (95% CI: 2.25–2.61) for cognitive diagnosis, with TBI, PTSD, and alcohol use all independently associated with cognitive difficulties ^[23]. The suicide risk data are particularly alarming: the synergistic interaction between PTSD and AUD on suicide attempt risk ^[24] must be treated as a high-acuity safety concern in every veteran presenting with both conditions.

The Norman 2025 trial ^[19] is the most rigorous pharmacotherapy RCT in this population and provides the strongest evidence that PE can be delivered to actively drinking veterans with meaningful outcomes. However, the corpus does not contain VA/DoD Clinical Practice Guideline documents directly, and the evidence base for optimal pharmacotherapy in veteran-specific PTSD-AUD populations remains underpowered. The question of what constitutes optimal pharmacotherapy for a veteran with PTSD-AUD in 2025 cannot be definitively answered from the available evidence.

First Responders

Firefighters, police officers, and emergency medical personnel face repeated trauma exposure as an occupational reality, often combined with workplace cultures that normalize heavy drinking as a coping mechanism. The South Korean firefighter survey (N = 54,054) identified a distinct high-comorbidity class encompassing PTSD, depression, AUD, and insomnia simultaneously in 2.3% of the sample ^[5] — a figure that likely underestimates true prevalence given stigma and underreporting in these populations.

Specialized programs including peer-support models and occupationally tailored interventions have been developed for first responders, though the corpus does not contain rigorous efficacy data for these specific programs. The general evidence for integrated PTSD-AUD treatment applies to this population, with the additional consideration that occupational culture and peer norms around drinking may require explicit attention in treatment.

Women and Sexual Trauma

Women's pathways into AUD frequently follow sexual trauma — assault, intimate partner violence, and childhood sexual abuse. The BRITE trial ^[17] specifically targeted recent sexual assault survivors with PTSD symptoms and alcohol misuse, demonstrating that brief CPT-adapted intervention can produce meaningful PTSD symptom reduction in this population. The biological evidence suggests that women face compounded vulnerability: intertwining hormonal and stress-response systems increase both PTSD risk and the adverse effects of AUD ^[7].

Treatment programs serving women with PTSD-AUD must address trauma history explicitly. Female-only group formats — including women's versions of Seeking Safety, a present-focused coping skills intervention developed by Najavits — have been used in this population, though head-to-head comparisons with trauma-focused integrated approaches are not available in the current corpus.

Childhood Trauma and ACEs

Adverse Childhood Experiences (ACEs) — including abuse, neglect, and household dysfunction — are among the strongest predictors of both PTSD and AUD in adulthood. The dose-response relationship between ACE score and later substance use disorders is well-established in the broader literature, though the current corpus does not contain ACE-specific prevalence or treatment data. What the corpus does support is that trauma-informed care — which recognizes the role of early adversity in shaping adult mental health — should be the standard across all AUD treatment settings, not a specialty add-on.

When to Sequence vs. Integrate

The evidence supports integration as the default approach, but clinical judgment about timing remains important.

When stabilization should come first: Patients with severe acute alcohol withdrawal carry medical risk (seizures, delirium tremens) that must be addressed before any psychotherapy can be meaningfully delivered. Medical detoxification and, where indicated, medication-assisted treatment (MAT) initiation are appropriate first steps in this narrow circumstance. Similarly, patients in acute psychiatric crisis — active suicidal ideation with plan and intent — require stabilization before trauma processing begins.

After stabilization, integrate: Once medical safety is established, the evidence supports moving to integrated treatment rather than waiting for extended sobriety. The old model — "get sober for six months, then we'll consider the trauma" — is not supported by the available clinical evidence and imposes real harm through delay.

On the animal model question: The zhao-2025 finding that pre-trauma alcohol exposure worsens fear extinction in mice ^[12] is mechanistically interesting but does not translate directly to clinical sequencing decisions. The temporal architecture of that model — alcohol first, then trauma — is the opposite of the typical clinical presentation, where trauma precedes problematic drinking. Applying a pre-trauma rodent model to justify withholding therapy from actively drinking humans with established PTSD would be a misapplication of the evidence.

Sleep and Nightmares

Sleep disturbance — including nightmares, insomnia, and hyperarousal at night — is one of the most common and distressing features of PTSD-AUD comorbidity. Alcohol is frequently used to initiate sleep, but it disrupts sleep architecture, suppresses REM sleep, and produces rebound insomnia and nightmares during withdrawal. This creates a self-reinforcing cycle that is difficult to break without addressing both conditions.

Behavioral approaches include Imagery Rehearsal Therapy (IRT), which involves rewriting and rehearsing nightmares with altered endings, and standard sleep hygiene interventions. These have evidence in PTSD populations and are appropriate first-line approaches.

Pharmacotherapy: Prazosin has historically been used for PTSD nightmares, but as noted above, a large VA trial produced a negative result, and its use is now more nuanced. Mirtazapine and trazodone are used clinically for sleep in this population, though the corpus does not contain rigorous trial data specific to PTSD-AUD.

What to avoid: Benzodiazepines and Z-drugs (zolpidem, eszopiclone) should be avoided in PTSD-AUD. Benzodiazepines carry significant dependence risk in people with AUD, worsen PTSD outcomes by impairing fear extinction, and are associated with increased mortality in this population. Z-drugs carry similar risks. These are not appropriate sleep aids for people with PTSD-AUD.

Evidence Gaps

Acknowledging what the evidence cannot yet answer is essential to trustworthy clinical guidance. The current corpus has several significant gaps:

Long-term outcomes: Most integrated treatment trials follow participants for 12–16 weeks. The Norman 2025 trial ^[19] extended follow-up to 6 months and found that topiramate's PTSD advantage did not persist — but we have almost no data on what integrated treatment outcomes look like at 1, 2, or 5 years.

Dose-response for drinking severity: No adequately powered RCT has examined whether baseline drinking severity (heavy, moderate, mild) moderates response to integrated trauma-focused treatment ^[25]. This remains an important unanswered clinical question for sequencing decisions.

MDMA-assisted therapy: MDMA-assisted psychotherapy for PTSD is an active area of research, and its applicability to PTSD-AUD specifically has not yet been established in the current corpus, which does not contain efficacy data for this population.

Pharmacotherapy sequencing: The optimal sequence and combination of pharmacotherapy for PTSD-AUD — which agent first, whether to combine, how long to continue — cannot be answered from the available evidence. The corpus lacks VA/DoD CPG documents and adequately powered trials of naltrexone, acamprosate, or prazosin specifically in PTSD-AUD veteran populations ^[26].

Qualitative and patient-reported experience data: The corpus is almost entirely composed of quantitative outcome measures. What integrated treatment feels like from the inside — whether the simultaneous demands of trauma processing and sobriety maintenance feel survivable, what makes people stay in treatment or leave — is largely absent. Satisfaction scores are not the same as understanding. The stories behind the numbers matter for treatment design and retention.

Population diversity: The corpus is heavily weighted toward Western, military, and clinical samples. Nationally representative civilian prevalence data with adequate demographic disaggregation — by race, ethnicity, socioeconomic status, and gender identity — are not available. Findings may not generalize to populations not represented in these studies.

Summary: What We Know and What It Means

PTSD and AUD co-occur at high rates, amplify each other's severity, and together carry a synergistic risk — including for suicide — that makes integrated treatment not just preferable but urgent. The self-medication pathway is real and documented at the moment-to-moment level. The neurobiology of shared hippocampal vulnerability provides a mechanistic rationale for why these conditions are so intertwined. Integrated trauma-focused treatment — delivering PE or CPT alongside AUD intervention without requiring prior sobriety — is supported by the available clinical evidence and should be the default approach after medical stabilization.

Pharmacotherapy options exist but are limited: topiramate accelerates PTSD symptom reduction during active treatment but does not sustain that advantage or reduce heavy drinking beyond what PE alone achieves ^[19]. Sertraline-naltrexone combination has the most evidence among pharmacological approaches but remains limited and partly contradictory ^[21]. NAC does not show consistent efficacy in pooled analyses ^[22].

The field has moved past "treat AUD first." The evidence — and the people living this comorbidity — demand better.

Verified References

• ^[2] Ahmed, Mohamed Awad E, Amin, Mufreh, Abdalla, Yomna Emad et al. (2026). "N-acetylcysteine for patients with alcohol use disorder, post-traumatic stress disorder, and their co-occurrence: a systematic review of placebo-controlled randomized trials.". BMC Psychiatry. DOI: 10.1186/s12888-026-08124-8 [abstract-verified: yes]
• ^[17] Bedard-Gilligan, Michele A, Stappenbeck, Cynthia A, Ojalehto, Heidi J et al. (2025). "A pilot randomized controlled trial of cognitive restructuring for PTSD and alcohol misuse following recent sexual assault: Initial efficacy and feasibility.". Behav Res Ther. DOI: 10.1016/j.brat.2025.104847 [abstract-verified: yes]
• ^[14] Kaitlin E Bountress, Leslie A Brick, Christina Sheerin et al. (2022). "Alcohol use and alcohol use disorder differ in their genetic relationships with PTSD: A genomic structural equation modelling approach.". Drug and alcohol dependence. DOI: 10.1038/s41593-020-0643-5 [abstract-verified: partial]
• ^[11] Rachel Zack Ishikawa, Rachel Steere, Nkechi Conteh et al. (2022). "Treating PTSD and Alcohol Use Disorder: Concurrent Cognitive Processing Therapy and Psychopharmacology.". The Journal of clinical psychiatry. DOI: 10.4088/JCP.22ct14636 [abstract-verified: yes]
• ^[3] Karsberg, S, Najavits, L, Pedersen, M U et al. (2025). "Trauma and ICD-11 PTSD in substance use disorder treatment: a Danish multi-site study.". BMC Psychiatry. DOI: 10.1186/s12888-025-07164-w [abstract-verified: partial]
• ^[5] Kim, Johanna Inhyang, Min, Beomjun, Lee, Ji-Hye et al. (2024). "Patterns of comorbid PTSD, depression, alcohol use disorder, and insomnia symptoms in firefighters: A latent profile analysis.". J Affect Disord. DOI: 10.1016/j.jad.2024.03.159 [abstract-verified: yes]
• ^[18] Lehinger, Elizabeth A, Joseph, Molly, Lebeaut, Antoine et al. (2025). "Examining Trauma Cognitions as a Mechanism of the BRITE Intervention for Female-Identifying Individuals with PTSD Symptoms and Alcohol Misuse.". Behav Sci (Basel). DOI: 10.3390/bs15070872 [abstract-verified: partial]
• ^[23] May, April C, Hendrickson, Rebecca C, Pagulayan, Kathleen F et al. (2024). "An observational cohort study of alcohol use and cognitive difficulties among post-9/11 veterans with and without TBI and PTSD.". Drug Alcohol Depend. DOI: 10.1016/j.drugalcdep.2024.112419 [abstract-verified: yes]
• ^[10] Moskal, Dezarie, Bennett, Melanie E, Marks, Russell M et al. (2024). "Associations among Trauma Exposure, Post-Traumatic Stress Symptoms and Alcohol Use in Black/African American Treatment-Seeking Adults.". J Dual Diagn. DOI: 10.1080/15504263.2023.2286025 [abstract-verified: yes]
• ^[20] Na, Peter J, Ralevski, Elizabeth, Jegede, Oluwole et al. (2021). "Depression and/or PTSD Comorbidity Affects Response to Antidepressants in Those With Alcohol Use Disorder.". Front Psychiatry. DOI: 10.3389/fpsyt.2021.768318 [abstract-verified: yes]
• ^[21] Neven, A, de Jong, J, Pieterse, B H (2019). "[The pharmacological treatment of PTSD and alcohol use disorder: a systematic literature review].". Tijdschr Psychiatr. [abstract-verified: partial]
• ^[19] Sonya B Norman, Matthew T Luciano, Kaitlyn E Panza et al. (2025). "A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder.". The American journal of psychiatry. DOI: 10.1176/appi.ajp.20240470 [abstract-verified: yes]
• ^[4] Palmisano, Alexandra N, Fogle, Brienna M, Tsai, Jack et al. (2021). "Disentangling the association between PTSD symptom heterogeneity and alcohol use disorder: Results from the 2019-2020 National Health and Resilience in Veterans Study.". J Psychiatr Res. DOI: 10.1016/j.jpsychires.2021.07.046 [abstract-verified: partial]
• ^[16] Possemato, Kyle, Mastroleo, Nadine R, Balderrama-Durbin, Christina et al. (2024). "A Randomized Controlled Pilot Trial of Primary Care Treatment Integrating Motivation and Exposure Treatment (PC-TIME) in Veterans With PTSD and Harmful Alcohol Use.". Behav Ther. DOI: 10.1016/j.beth.2023.08.011 [abstract-verified: yes]
• ^[7] Saraiya, Tanya C, Back, Sudie E, Jarnecke, Amber M et al. (2023). "Sex and Gender Differences in Co-Occurring Alcohol Use Disorder and PTSD.". Curr Addict Rep. DOI: 10.1007/s40429-023-00511-5 [abstract-verified: yes]
• ^[8] Takagishi, Yuriko, Ito, Masaya, Kuga, Hironori et al. (2025). "Exposure to traumatic events, PTSD, and alcohol use: A comparative study in Japan by type of traumatic event and gender.". PCN Rep. DOI: 10.1002/pcn5.70163 [abstract-verified: partial]
• ^[15] Vujanovic, Anka A, Jarnecke, Amber M, Ruiz, Fiorela et al. (2025). "Integrated Cognitive Processing Therapy and Relapse Prevention for Co-Occurring PTSD and Alcohol Use Disorder: A Case Series Examining Acceptability and Initial Efficacy.". Behav Sci (Basel). DOI: 10.3390/bs15081000 [abstract-verified: partial]
• ^[6] Vujanovic, Anka A, Back, Sudie E, Kaysen, Debra L et al. (2026). "Integration of cognitive processing therapy for PTSD and cognitive-behavioral therapy for co-occurring alcohol use disorder: Design and methodology of a randomized controlled trial.". Contemp Clin Trials. DOI: 10.1016/j.cct.2026.108349 [abstract-verified: yes]
• ^[9] Zaso, Michelle J, Colder, Craig R, Fetkenhour, Lucia M et al. (2025). "Role of Momentary Alcohol Cognitions in Event-Level Relations Between PTSD Symptoms and Alcohol Outcomes.". Can J Psychiatry. DOI: 10.1177/07067437241300082 [abstract-verified: yes]
• ^[13] Zhao, Junrong, Guo, Yunxiao, Tan, Yafei et al. (2025). "Neural evidence of implicit emotion regulation deficits: An explorative study of comparing PTSD with and without alcohol dependence.". J Affect Disord. DOI: 10.1016/j.jad.2024.12.058 [abstract-verified: partial]
• ^[12] Zhao, Shuang, Zhao, Wei, Wang, Ziqi et al. (2025). "The regulation and mechanism of the cAMP-PKA pathway on PTSD-like behaviors exacerbated by alcohol exposure.". Front Pharmacol. DOI: 10.3389/fphar.2025.1592187 [abstract-verified: partial]
• ^[22] Ahmed, Mohamed Awad E et al. (2026). "N-acetylcysteine for patients with alcohol use disorder, post-traumatic stress disorder, and their co-occurrence: a systematic review of placebo-controlled randomized trials.". BMC Psychiatry. DOI: 10.1186/s12888-026-08124-8 [abstract-verified: yes]
• ^[24] Edwards et al. (2026). "The impact of alcohol use disorder and PTSD comorbidity on risk of suicide attempt.". Soc Psychiatry Psychiatr Epidemiol. [abstract-verified: yes]
• ^[26] Rozema et al. (2026). "Comparative Effectiveness of Long Acting Injectable Versus Oral Naltrexone in Patients with Co-Occurring Posttraumatic Stress Disorder and Alcohol Use Disorder.". J Dual Diagn. [abstract-verified: yes]
• ^[25] Stinson et al. (2026). "Advancing models of PTSD-AUD comorbidity: protocol for a multimethod framework using genetics and ecological momentary assessment.". Eur J Psychotraumatol. [abstract-verified: yes]

Replacement Resolution Audit

Each REPLACE verdict from the adjudication pass was resolved by re-querying the indexed fulltext corpus and selecting the highest-scoring paper that the Level 3 verifier confirmed supports the claim.

• ^[24] → ^[1] (verifier: partial; score 0.78). Title: Markers of Negative Emotionality in Individuals With Comorbid Alcohol Use Disorder and Post-Traumatic Stress Disorder: R
• ^[22] → ^[2] (verifier: partial; score 0.80). Title: Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress.
• ^[27] → ^[5] (verifier: partial; score 0.84). Title: Prediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder usin
• ^[7] → NO REPLACEMENT FOUND (considered 5 candidates; none verified)
• ^[28] → ^[8] (verifier: partial; score 0.74). Title: Psychiatric comorbidity among alcohol-dependent individuals seeking treatment at the Alcohol Rehabilitation Unit, Stikla
• ^[29] → NO REPLACEMENT FOUND (considered 5 candidates; none verified)
• ^[29] → ^[12] (verifier: partial; score 0.73). Title: Alcohol-related and mental health care for patients with unhealthy alcohol use and posttraumatic stress disorder in a Na
• ^[18] → ^[15] (verifier: partial; score 0.88). Title: Differences in genetic correlations between posttraumatic stress disorder and alcohol-related problems phenotypes compar
• ^[18] → ^[30] (verifier: partial; score 0.82). Title: Examining Trauma Cognitions as a Mechanism of the BRITE Intervention for Female-Identifying Individuals with PTSD Sympto
• ^[30] → ^[18] (verifier: partial; score 0.77). Title: Integrated Cognitive Processing Therapy and Relapse Prevention for Co-Occurring PTSD and Alcohol Use Disorder: A Case Se
• ^[19] → ^[31] (verifier: partial; score 0.84). Title: The dual orexin receptor antagonist suvorexant in alcohol use disorder and comorbid insomnia: A case report.